News
The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...
The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...
As Azurity Pharmaceuticals rethinks its manufacturing footprint, the privately held company is parting ways with a clutch of ...
Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...
After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...
It may not be an Olympic year, but Humana is still firing up some competition this summer. | It may not be an Olympic year, ...
For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...
A weekend focused on women’s health and women’s basketball, all in Eli Lilly’s home state of Indiana? Consider that a layup ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results